Transgene, NEC and BostonGene expand neoantigen cancer vaccine collaboration
Transgene, NEC Corporation and BostonGene announce the expansion of their collaboration for the randomised Phase I/II trial of TG4050, an individualised therapeutic vaccine for patients with head and neck cancers